WHO ICTRP trial
Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+…
EUCTR2018-004336-30-AT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-004336-30-AT |
|---|---|
| Public title | Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL. |
| Scientific title | Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL. |
| Primary sponsor | Novartis Pharma AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Austria;United States;Japan;Italy;Australia;France;Germany;Spain |
| Conditions | ALL, CLL/SLL and DLBCL and High-Risk LBCL.;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: Rapcabtagene autoleucel Product Code: YTB323 Pharmaceutical Form: Suspension for injection INN or Proposed INN: Rapcabtagene autoleucel Current Sponsor code: YTB323 Concentration unit: Other Concentration type: range… |
| Registration date | Oct 21, 2019 |
| Target size | 240 |
| Secondary IDs | CYTB323A12101 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: